Cytoprotective drugs in the prevention of ethanol-induced experimental gastric mucosal damage: a morphological study.
Various so-called "cytoprotective" agents (sucralfate, carbenoxolone, 16,16-dimethyl-PGE2, sulglycotide and Maalox TC) have been tested on rats, with the aim of quantifying their capability to prevent ethanol-induced gastric mucosal damage. Rats fasted for 48 hours received 1 ml of 80% ethanol by oral gavage, after prior oral treatment with placebo or one of the above-mentioned drugs u.i.d. for 5 consecutive days. Six hours after ethanol administration, the animals were sacrificed and the stomach was removed and processed for computerized macroscopic assessment of the damaged surface and for structural (light microscopy) and ultrastructural (scanning and transmission electron microscopy) studies. The results obtained demonstrate that ethanol injury caused extensive mucosal necrosis of the glandular region of the stomach, an event that was effectively reduced in rats treated with 16,16-dm-PGE2, carbenoxolone or sulglycotide. These drugs appeared to preserve the mucosa, with morphology comparable to that of normal noninjured rats - in contrast to the other drugs investigated. These data confirm the cytoprotective properties of sulglycotide in particular, which was the most potent agent for preventing the development of ethanol-induced acute lesions of the gastric mucosa.
Dipartimento di Biopatologia Umana, Università La Sapienza, Roma, Italy.
E
E
Gaudio
F
F
Carpino
V
V
Petrozza
G
G
Bianchi
P
P
Alberico
M
M
Melis
F
F
Carlei
N J
NJ
Lygidakis
D015064:16,16-Dimethylprostaglandin E2 / Q000627:therapeutic use; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000818:Animals; D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002229:Carbenoxolone / Q000627:therapeutic use; D004338:Drug Combinations; D000431:Ethanol / Q000009:adverse effects*; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D008276:Magnesium Hydroxide / Q000627:therapeutic use; D008297:Male; D008855:Microscopy, Electron, Scanning; D051381:Rats; D012795:Sialoglycoproteins / Q000627:therapeutic use; D013392:Sucralfate / Q000627:therapeutic use
D000863:Antacids; D000897:Anti-Ulcer Agents; D004338:Drug Combinations; D012795:Sialoglycoproteins; C009354:sulglicotide; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000431:Ethanol; D013392:Sucralfate; D000536:Aluminum Hydroxide; D015064:16,16-Dimethylprostaglandin E2; D002229:Carbenoxolone; D008276:Magnesium Hydroxide